Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The wedding too
Multiple sclerosis and regulatory T cells
In 2023, as GLP-1s were becoming increasingly used for weight loss, the FDA turned their attention to several other less-common peptides
Kayli Anderson, RDN Medical Reviewer Kayli Anderson has over a decade of experience in nutrition, culinary education, and lifestyle medicine
When you are shopping for a formula to add to your daily stack, use this checklist to ensure you are getting a clean, high-quality product
Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year September 10, 2025 According to a new data update from REGENXBIO's pivotal phase 1/2/3 CAMPSIITE clinical trial (NCT03566043) evaluating clemidsogene lanparvovec (RGX-121), an investigational adeno-associated virus (AAV) vector-based gene therapy for mucopolysaccharidosis type 2 (MPSII, also known as Hunter syndrome), 13 patients treated in the pivotal phase have shown an 82% reduction in heparan sulfate (HS) D2S6 levels in the cerebrospinal fluid (CSF) through 1 year posttreatment
